Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.55 |
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536503 | 0.86 | PARP10 (0.50) | PARP10PARP15PARP2NR1H4 | |
| SCHEMBL27834128 | 0.85 | PARP10 (0.47) | MAOBMAOAPARP10PARP15PARP2 | |
| SCHEMBL18374257 | 0.84 | PARP10 (0.56) | MAOBMAOAPARP10PARP15PARP2 | |
| SCHEMBL116837 | 0.82 | MAOB (0.52) | MAOBMAOA | |
| SCHEMBL983929 | 0.82 | PARP10 (0.53) | PARP10PARP15PARP2ACACBACACA | |
| SCHEMBL5085580 | 0.81 | PARP10 (0.60) | MAOBMAOAPARP10PARP15 | |
| SCHEMBL3428815 | 0.81 | PARP10 (0.49) | MAOBPARP10PARP15PARP2ACACB | |
| SCHEMBL3652542 | 0.79 | MAOB (0.61) | MAOBMAOA | |
| SCHEMBL8651126 | 0.78 | PARP10 (0.48) | PARP10PARP15PARP2ACACBACACA | |
| SCHEMBL3720859 | 0.78 | PARP10 (0.46) | PARP10PARP15PARP2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAOB 2146/4885MAOA 2615/4885PARP10 4573/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MAOB 2146/4885MAOA 2615/4885PARP10 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.